Genmab AS (MEX:GMABN) Cyclically Adjusted Book per Share: MXN789.27 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MEX:GMABN Genmab AS MEX:GMABN
93 GF Score
Price MXN5,000.66
GF Value MXN5,659.54
Valuation Fairly Valued
! 5 Warning Signs
View Full Analysis

What is Genmab AS Cyclically Adjusted Book per Share?

Genmab AS MEX:GMABN 93 Cyclically Adjusted Book per Share is MXN789.27 as of Jun. 2026. GuruFocus rates MEX:GMABN with a GF Score™ of 93/100 and a GF Value™ of MXN5,659.54 (Fairly Valued). The stock has 5 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Genmab AS's adjusted book value per share for the three months ended in Jun. 2026 was MXN1,691.847. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is MXN789.27 for the trailing ten years ended in Jun. 2026.

During the past 12 months, Genmab AS's average Cyclically Adjusted Book Growth Rate was 20.40% per year. During the past 3 years, the average Cyclically Adjusted Book Growth Rate was 24.60% per year. During the past 5 years, the average Cyclically Adjusted Book Growth Rate was 30.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Book Growth Rate of Genmab AS was 40.30% per year. The lowest was 24.60% per year. And the median was 33.25% per year.

As of today (2026-08-14), Genmab AS's current stock price is MXN5000.66. Genmab AS's Cyclically Adjusted Book per Share for the quarter that ended in Jun. 2026 was MXN789.27. Genmab AS's Cyclically Adjusted PB Ratio of today is 6.34.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Genmab AS was 39.38. The lowest was 4.40. And the median was 20.57.


Genmab AS  (MEX:GMABN) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Genmab AS's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=5000.66/789.27
=6.34

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Genmab AS was 39.38. The lowest was 4.40. And the median was 20.57.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Genmab AS Cyclically Adjusted Book per Share Related Terms


Genmab AS Cyclically Adjusted Book per Share Historical Data

* Premium members only.

The historical data trend for Genmab AS's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Genmab AS Cyclically Adjusted Book per Share Chart

Genmab AS Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 417.40 499.09 522.46 897.02 889.46

Genmab AS Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 963.65 827.19 889.46 892.59 789.27

MEX:GMABN vs VRTX, REGN, RVMD: Cyclically Adjusted Book per Share Comparison

For the Biotechnology subindustry, Genmab AS's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Genmab AS Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Genmab AS's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Genmab AS's Cyclically Adjusted PB Ratio falls into.


MEX:GMABN
93GF Score
Genmab AS MEX:GMABN
Cyclically Adjusted Book per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Genmab AS Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Genmab AS's adjusted Book Value per Share data for the three months ended in Jun. 2026 was:

Adj_Book= Book Value per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=1691.847/122.9700*122.9700
=1,691.847

Current CPI (Jun. 2026) = 122.9700.

Genmab AS Quarterly Data

Book Value per Share CPI Adj_Book
201609 190.331 100.200 233.583
201612 233.708 100.300 286.531
201703 223.316 101.200 271.355
201706 247.875 101.200 301.198
201709 257.166 101.800 310.645
201712 324.966 101.300 394.482
201803 320.239 101.700 387.215
201806 341.374 102.300 410.350
201809 336.029 102.400 403.530
201812 393.105 102.100 473.459
201903 385.275 102.900 460.420
201906 394.131 102.900 471.004
201909 557.090 102.900 665.747
201912 611.932 102.900 731.286
202003 766.516 103.300 912.473
202006 954.659 103.200 1,137.543
202009 985.071 103.500 1,170.379
202012 961.062 103.400 1,142.957
202103 990.204 104.300 1,167.453
202106 983.135 105.000 1,151.392
202109 1,044.269 105.800 1,213.741
202112 1,054.770 106.600 1,216.745
202203 1,032.680 109.900 1,155.493
202206 1,051.664 113.600 1,138.408
202209 1,076.598 116.400 1,137.365
202212 1,171.053 115.900 1,242.488
202303 1,099.953 117.300 1,153.122
202306 1,101.939 116.400 1,164.136
202309 1,175.135 117.400 1,230.889
202312 1,217.791 116.700 1,283.220
202403 1,197.657 118.400 1,243.884
202406 1,283.288 118.500 1,331.696
202409 1,482.288 118.900 1,533.027
202412 1,686.115 118.900 1,743.831
202503 1,710.475 120.200 1,749.893
202506 1,623.212 120.700 1,653.740
202509 1,713.540 121.600 1,732.846
202512 1,709.108 121.200 1,734.068
202603 1,669.004 121.680 1,686.698
202606 1,691.847 122.970 1,691.847

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

What does a Cyclically Adjusted Book per Share of MXN789.27 mean?
Genmab AS (MEX:GMABN) has a Cyclically Adjusted Book per Share of MXN789.27 as of Jun. 2026. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Genmab AS and its competitors.
Is Genmab AS's Cyclically Adjusted Book per Share too high?
Genmab AS's current Cyclically Adjusted Book per Share is MXN789.27. Overall, Genmab AS has a GF Score™ of 93/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Genmab AS's Cyclically Adjusted Book per Share compare to VRTX and REGN?
Genmab AS's Cyclically Adjusted Book per Share of MXN789.27 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Book per Share for a Biotechnology company?
A good Cyclically Adjusted Book per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Book per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Book per Share mean?
A high Cyclically Adjusted Book per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Genmab AS and its competitors. Genmab AS's current Cyclically Adjusted Book per Share is MXN789.27. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genmab AS stock overvalued right now?
Based on GuruFocus' analysis, Genmab AS (MEX:GMABN) is currently considered Fairly Valued. The stock's GF Value™ is MXN5,659.54, compared to a current price of MXN5,000.66 — trading 11.6% below its estimated fair value. The current Cyclically Adjusted Book per Share is MXN789.27. Genmab AS's overall GF Score™ is 93/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Book per Share calculated?
Cyclically Adjusted Book per Share is calculated from a company's financial statements. For Genmab AS (MEX:GMABN), the current Cyclically Adjusted Book per Share is MXN789.27 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Genmab AS (MEX:GMABN) Overvalued in 2026?

Based on GuruFocus' analysis, Genmab AS stock appears to be undervalued. The current stock price of MXN5,000.66 is trading 11.6% below its estimated GF Value™ of MXN5,659.54. GuruFocus considers Genmab AS to be Fairly Valued.

Key valuation signals for MEX:GMABN:

  • Cyclically Adjusted Book per Share: MXN789.27
  • GF Value™: MXN5,659.54 vs. price of MXN5,000.66 (11.6% below fair value)
  • GF Score™: 93/100 with 5 warning signs

No single metric tells the full story. See the MEX:GMABN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Genmab AS Business Description

Address Carl Jacobsens Vej 30, Valby, DNK, 2500
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.
93GF Score

Get the complete analysis for MEX:GMABN

Cyclically Adjusted Book per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN5,000.66
Price
MXN5,659.54
GF Value